We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




“Over-the-Wire” Device Treats Resistant High Blood Pressure

By HospiMedica International staff writers
Posted on 12 Feb 2013
A next-generation renal denervation device uses ultrasound energy for complete circumferential denervation more consistently and efficiently than the standard of care radiofrequency (RF) ablation catheter.

The Paradise minimally invasive 2-mm diameter over-the-wire (OTW) ultrasound device is used for treating resistant high blood pressure in a three-fold approach; first, the device is designed to penetrate up to 8 millimeters into the tissue; second, the device delivers heat circumferentially, to target all of the renal nerves in one location; and third, this is achieved while simultaneously cooling the artery wall’s surface to protect the vessel. More...


Treatment parameters of the second-generation device have been enhanced to reduce energy delivery to 30 seconds for maximizing cooling of the endothelium, and efficiently treating the nerves circumferentially. The Paradise 2 mm OTW ultrasound device is a product of ReCor Medical (Menlo Park, CA, USA), and has received the European Community CE marking of approval.

“Our unique approach is in stark contrast to RF, which is limited in its depth of penetration to just a few millimeters, due to inconsistent arterial wall contact, as well as its inability to heat circumferentially in any given location,” said Mano Iyer, CEO of ReCor Medical. “Renal nerves are actually much further at depth than previously thought, and run circumferentially around the renal arteries, which underscore the Paradise ultrasound advantage.”

Renal denervation is a, endovascular catheter based procedure for treating resistant hypertension. By applying energy pulses to the renal arteries, the nerves in the vascular wall (adventitia layer) can be denervated. This causes reduction of renal sympathetic afferent and efferent activity and blood pressure can be decreased. Early data from international clinical trials is promising, demonstrating an average blood pressure reduction of approximately 30 mm Hg at three-year follow up in patients with treatment-resistant hypertension.

Related Links:

ReCor Medical



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.